Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
Clinical cancer genomic profiling
D Chakravarty, DB Solit - Nature Reviews Genetics, 2021 - nature.com
Technological innovation and rapid reduction in sequencing costs have enabled the
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
IW Deveson, B Gong, K Lai, JS LoCoco… - Nature …, 2021 - nature.com
Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology,
but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here …
but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here …
DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism
Cancer-associated venous thromboembolism (VTE) is a major source of oncologic cost,
morbidity and mortality. Identifying high-risk patients for prophylactic anticoagulation is …
morbidity and mortality. Identifying high-risk patients for prophylactic anticoagulation is …
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied
mostly in small cohorts without sufficient follow-up to determine its influence on overall …
mostly in small cohorts without sufficient follow-up to determine its influence on overall …
A performance comparison of commonly used assays to detect RET fusions
Purpose: Selpercatinib and pralsetinib induce deep and durable responses in patients with
advanced RET fusion–positive lung and thyroid cancer. RET fusion testing strategies with …
advanced RET fusion–positive lung and thyroid cancer. RET fusion testing strategies with …
[HTML][HTML] Retrospective evaluation of somatic alterations in cell-free DNA from blood in retinoblastoma
DH Abramson, D Mandelker, JH Francis, IJ Dunkel… - Ophthalmology …, 2021 - Elsevier
Purpose Analysis of circulating tumor DNA (ctDNA) in the plasma of patients with
retinoblastoma and simulating lesions. Design Retrospective cross-sectional study of the …
retinoblastoma and simulating lesions. Design Retrospective cross-sectional study of the …
NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: a prospective, multicenter study in China
Q Zheng, X Lin, W Qi, J Yin, J Li, Y Wang, W Wang… - Lung Cancer, 2024 - Elsevier
Abstract Objectives Comprehensive data using Next-Generation Sequence (NGS) and
fluorescence in situ hybridization (FISH) for detecting MET amplification is limited in Chinese …
fluorescence in situ hybridization (FISH) for detecting MET amplification is limited in Chinese …
Mutant-RB1 circulating tumor DNA in the blood of unilateral retinoblastoma patients: What happens during enucleation surgery: A pilot study
DH Abramson, DL Mandelker, AR Brannon, IJ Dunkel… - Plos one, 2023 - journals.plos.org
Cell free DNA (cf DNA) and circulating tumor cell free DNA (ct DNA) from blood (plasma) are
increasingly being used in oncology for diagnosis, monitoring response, identifying cancer …
increasingly being used in oncology for diagnosis, monitoring response, identifying cancer …
Matched molecular profiling of cell-free DNA and tumor tissue in patients with advanced clear cell renal cell carcinoma
PURPOSE The clinical utility of cell-free DNA (cfDNA) as a biomarker for advanced clear cell
renal cell carcinoma (ccRCC) remains unclear. We evaluated the validity of cfDNA-based …
renal cell carcinoma (ccRCC) remains unclear. We evaluated the validity of cfDNA-based …